Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients

Objective: Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality, with rat sarcoma (RAS) and proto-oncogene B-raf (BRAF) mutations associated with worse prognosis in metastatic settings. Despite advances in treatment, the optimal chemotherapy backbone combined with bevaciz...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Alper TOPAL, Goncagül AKDAĞ, Ayşegül DUMLUDAĞ, Çağlar KÖSEOĞLU, Ömer Faruk KUZU, Hüseyin ATACAN, Baran Can AYTAÇ, Gizem YILDIRIM, Sedat YILDIRIM, Hacer Şahika YILDIZ, Gülsema YILDIRAN KESKİN, Nuri KARADURMUŞ
פורמט: Artigo
שפה:Inglês
יצא לאור: Turkish Society of Oncology 2025-08-01
סדרה:Journal of Oncological Sciences
נושאים:
colorectal cancer
kras
braf
folfox
folfiri
bevacizumab
גישה מקוונת:https://journalofoncology.org/articles/comparison-of-first-line-folfox-versus-folfiri-in-ras-mutant-metastatic-colorectal-cancer-patients/doi/jos.galenos.2025.2025-3-22
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים